NGLY1 and melanoma: Importantly, in vitro and in vivo experiments indicated that genetic and pharmacological inhibition of NGLY1 in melanoma cells exerts a strong anti-tumor effect, promotes apoptosis, and renders melanoma cells more sensitive to other chemotherapeutic agents, including bortezomib [110].